MetaCap

Ispire Technology (ISPR) vs MediWound (MDWD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

MediWound (MDWD) has outperformed Ispire Technology (ISPR) over the past year, losing 26.7% versus a loss of 39.0%. MediWound is the larger company by market cap ($163.7 million vs $81.4 million), about 2.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ISPR-38.96%MDWD-26.74%
+65%+3%-58%
Oct 7, 20251 yearOct 7, 2026
ISPR-80.08%MDWD+1.90%
+85%-3%-91%
Apr 3, 20235 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ISPR versus MDWD key metrics
MetricISPRMDWD
Share price$1.41$12.68
Market cap$81.44M$163.70M
1-day change+0.01%-1.32%
YTD return-49.64%-30.39%
1-year return-38.96%-26.74%
5-year return—-46.17%
Forward P/E70.51—
EPS (TTM)$-0.58$-2.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$3.87$20.03
52-week low$1.01$12.52
Distance from 52-week high-63.56%-36.69%
Analyst consensus—strong_buy
Avg. price target upside—+141.88%
Average volume35.98K84.01K
Shares outstanding57.75M12.91M
Employees—121
SectorHealth CareHealth Care
Industry Medicinal Chemicals and Botanical Products Medicinal Chemicals and Botanical Products

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MediWound is about 2.0 times larger than Ispire Technology by market value ($163.70M vs $81.44M).
  • MDWD has outperformed ISPR by 12.2 percentage points over the past year.

About MediWound

MDWD stock →

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Health Care · Medicinal Chemicals and Botanical Products · 121 employees

ISPR vs MDWD FAQ

Which is bigger, Ispire Technology or MediWound?

MediWound (MDWD) is larger, with a market capitalization of $163.70M compared with $81.44M for Ispire Technology (ISPR).

Which stock has performed better over the past year, ISPR or MDWD?

MDWD returned -26.74% over the past 12 months, compared with -38.96% for ISPR (price return, excluding dividends). Past performance does not predict future results.

Are Ispire Technology and MediWound in the same industry?

Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.

More comparisons